Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials
- 19 January 2005
- Vol. 23 (9) , 1170-1177
- https://doi.org/10.1016/j.vaccine.2004.08.032
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Leishmania/HIV co-infections: epidemiology in EuropePathogens and Global Health, 2003
- Anthroponotic Cutaneous Leishmaniasis, Kabul, AfghanistanEmerging Infectious Diseases, 2003
- Health organisation warns that kala-azar has returned to South SudanThe Lancet, 2002
- The immunology of susceptibility and resistance to Leishmania major in miceNature Reviews Immunology, 2002
- Strategic emphases for tropical diseases research: a TDR perspectiveTrends in Parasitology, 2002
- Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in SudanThe Lancet, 2000
- A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in IranPublished by Elsevier ,1999
- Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, IranThe Lancet, 1998
- LeishmaniasisClinics in Dermatology, 1996
- Experiences with vaccines against cutaneous leishmaniasis: of men and miceParasitology, 1989